Drug maker Divi's Laboratories on Saturday reported a consolidated net profit of Rs 557.11 crore for the quarter ended June 30. That marked a year-on-year rise of 13.22 percent compared with the net profit of Rs 492.06 crore that it had reported for the corresponding period a year ago.
Its revenue from operations grew 13.30 percent on year to Rs 1,960.64 crore in the April-June period, according to a regulatory filing.
Analysts in a CNBC-TV18 poll had expected Divi’s Labs to post a rise of 15 percent in net profit and revenue growth of around 15 percent .
Total expenses came in at Rs 1,182.13 crore in the June quarter, as against Rs 1,086.82 crore in the year-ago period. The cost of raw materials rose 68.93 percent to Rs 784.29 crore.
The consolidated earnings included the numbers of the pharmaceutical company's subsidiaries Divis Laboratories (USA) Inc and Divi's Laboratories Europe AG.
On Friday, the Divi's Laboratories stock declined 0.15 percent to end at Rs 4,915.90 apiece on BSE. The S&P BSE Sensex index shed 0.39 percent to settle at 54,277.72, putting an end to a four-day winning streak.
First Published: Aug 7, 2021 4:39 PM IST
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!
Phase five Lok Sabha polls: Rae Bareli, Amethi among 14 UP seats going to polls on Monday
May 19, 2024 1:03 PM
AAP protest walk: Arvind Kejriwal challenges BJP to arrest entire party, Delhi Police imposes Section 144
May 19, 2024 12:26 PM
Terror attacks in Kashmir raise concerns ahead of May 20 and May 25 election
May 19, 2024 12:15 PM